41712 Federal Register / Vol. 74, No. 158 / Tuesday, August 18, 2009 / Notices 

ACTION: Notice; reopening of comment 

period. 

SUMMARY: The Food and Drug 

Administration (FDA) is reopening until 

November 6, 2009, the comment period 

for the notice of public meeting and 

request for comments that appeared in 

the Federal Register of June 3, 2009 (74 

FR 26712). In the notice of public 

meeting and request for comments, 

FDA’s Transparency Task Force 

requested comments on ways in which 

FDA can make useful and 

understandable information about FDA 

activities and decision making more 

readily available to the public. The 

agency is taking this action because the 

agency is planning a second public 

meeting this fall and is reopening the 

comment period to allow interested 

persons additional time to submit 

comments. 

DATES: Submit written or electronic 

comments by November 6, 2009. 

ADDRESSES: Submit written comments 

to the Division of Dockets Management 

(HFA–305), Food and Drug 

Administration, 5630 Fishers Lane, rm. 

1061, Rockville, MD 20852. Submit 

electronic comments to http:// 

www.regulations.gov. All such 

comments should be identified with the 

docket number found in brackets in the 

heading of this document. 

FOR FURTHER INFORMATION CONTACT: Afia 

Asamoah, Office of the Commissioner, 

Food and Drug Administration, 10903 

New Hampshire Ave., Bldg. 1, rm. 2208, 

Silver Spring, MD 20993, 301–796– 

4625, FAX: 301–847–3531, e-mail: 

Afia.Asamoah@fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: In the 

Federal Register of June 3, 2009 (74 FR 

26712), FDA published a notice of 

public meeting and request for 

comments on ways in which FDA can 

make useful and understandable 

information about FDA activities and 

decisionmaking more readily available 

to the public, in a manner compatible 

with the agency’s goal of protecting 

confidential information, as appropriate. 

Interested persons were given until 

August 7, 2009, to submit comments. 

The agency is planning to hold a second 

meeting in the fall of 2009 about these 

issues and is reopening the comment 

period until November 6, 2009. FDA has 

also established an online blog at http:// 

fdatransparencyblog.fda.gov in which 

interested persons may provide 

feedback on specific topics. The blog is 

expected to run through November 

2009. 

Interested persons may submit written 

or electronic comments to the Division 

of Dockets Management (see 

ADDRESSES). Submit a single copy of 

electronic comments to http:// 

www.reguations.gov or two paper copies 

of any mailed comments, except that 

individuals may submit one paper copy. 

Comments are to be identified with the 

docket number found in brackets in the 

heading of this document. Received 

comments may be seen in the Division 

of Dockets Management between 9 a.m. 

and 4 p.m., Monday through Friday. 

Dated: August 12, 2009. 

Jeffrey Shuren, 

Associate Commissioner for Policy and 

Planning. 

[FR Doc. E9–19778 Filed 8–17–09; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Board of Scientific Counselors, 

National Center for Public Health 

Informatics (BSC, NCPHI) 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC), 

announces the following meeting of the 

aforementioned committee: 

Time and Date: 8:30 a.m.–5 p.m., 

September 2, 2009. 

Place: Hyatt Regency, 265 Peachtree 

Street NE., Atlanta, Georgia, 30303 Tel: 

(404) 577–1234, Fax: (404) 588–4137. 

Maps & Directions 

This meeting will also be 

teleconferenced: Toll Free Number: 

(866) 713–5586, Participant’s pass code 

4624038. 

Status: Open to the public, limited 

only by the space available. 

Purpose: The committee shall advise 

the Secretary, HHS, and the Director, 

CDC, concerning strategies and goals for 

the programs and research within the 

national centers; shall conduct peerreview of scientific programs; and 

monitor the overall strategic direction 

and focus of the national centers. The 

board, after conducting its periodic 

reviews, shall submit a written 

description of the results of the review 

and its recommendations to the 

Director, CDC. The board shall perform 

second-level peer review of applications 

for grants-in-aid for research and 

research training activities, cooperative 

agreements, and research contract 

proposals relating to the broad areas 

within the national center. 

Matters to be Discussed: The board 

will discuss BSC, NCPHI-related 

matters, including an update on NCPHI 

Programs and other BSC-related 

activities. 

Agenda items are subject to change as 

priorities dictate. 

Contact Person for More Information: 

Dr. Scott McNabb, National Center for 

Public Health Informatics, CDC, 1600 

Clifton Road, NE., Mailstop E–78, 

Atlanta, Georgia 30333, Telephone (404) 

498–6427, Fax (404) 498–6235. 

The Director, Management Analysis 

and Services Office, has been delegated 

the authority to sign Federal Register 

notices pertaining to announcements of 

meetings and other committee 

management activities for both the CDC 

and the Agency for Toxic Substance and 

Disease Registry. 

Dated: August 10, 2009. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. E9–19754 Filed 8–17–09; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of General Medical 

Sciences; Notice of Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of a meeting of the 

National Advisory General Medical 

Sciences Council. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Advisory 

General Medical Sciences Council. 

Date: September 10–11, 2009. 

Closed: September 10, 2009, 8:30 a.m. to 5 

p.m. 


jlentini on DSKJ8SOYB1PROD with NOTICES
Federal Register / Vol. 74, No. 158 / Tuesday, August 18, 2009 / Notices 41713 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Natcher Building, Conference Rooms E1 & 

E2, 45 Center Drive, Bethesda, MD 20892. 

Open: September 11, 2009, 8:30 a.m. to 

adjournment. 

Agenda: For the discussion of program 

policies and issues, opening remarks, report 

of the Director, NIGMS, and other business 

of the Council. 

Place: National Institutes of Health, 

Natcher Building, Conference Rooms E1 & 

E2, 45 Center Drive, Bethesda, MD 20892. 

Contact Person: Ann A. Hagan, PhD, 

Associate Director for Extramural Activities, 

NIGMS, NIH, DHHS, 45 Center Drive, Room 

2AN24H, MSC6200, Bethesda, MD 20892– 

6200. (301) 594–4499. 

hagana@nigms.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

onto the NIH campus. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

campus. Visitors will be asked to show one 

form of identification (for example, a 

government-issued photo ID, driver’s license, 

or passport) and to state the purpose of their 

visit. 

Information is also available on the 

Institute’s/Center’s home page: http:// 

www.nigms.nih.gov/about/ 

advisory_council.html, where an agenda and 

any additional information for the meeting 

will be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.375, Minority Biomedical 

Research Support; 93.821, Cell Biology and 

Biophysics Research; 93.859, Pharmacology, 

Physiology, and Biological Chemistry 

Research; 93.862, Genetics and 

Developmental Biology Research; 93.88, 

Minority Access to Research Careers; 93.96, 

Special Minority Initiatives, National 

Institutes of Health, HHS) 

Dated: August 10, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–19663 Filed 8–17–09; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2009–N–0376] 

Office of the Commissioner 

Reorganization; Statement of 

Organizations, Functions, and 

Delegations of Authority 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) has reorganized 

the Office of the Commissioner (OC). 

This reorganization includes the 

organizations and their substructure 

components as listed in this document. 

This reorganization includes the realignment of four Deputy-level offices 

within the Office of the Commissioner: 

the Office of the Chief Scientist; the 

Office of Administration (formerly titled 

the Office of Operations); the Office of 

Foods; and the Office of Policy, 

Planning and Budget (formerly titled the 

Office of Policy, Planning and 

Preparedness). 

FOR FURTHER INFORMATION CONTACT: 

Vanessa Starks, Office of Management 

Programs (HFA–400), Food and Drug 

Administration, 5600 Fishers Lane, rm. 

6B–42, Rockville, MD 20857, 301–827– 

1463. 

Office of the Chief Scientist: The 

organizational change will allow the 

agency to better focus the science and 

research activities under the Chief 

Scientist. Re-alignments under the 

Office of the Chief Scientist will include 

the Office of Counter-Terrorism and 

Emerging Threats, Office of Critical Path 

Programs, Office of Scientific Integrity, 

and the Office of Science and 

Innovation. 

Office of Administration: The Office 

of Operations will be re-titled the Office 

of Administration. The Office of 

Administration will be restructured to 

strengthen agency wide management 

programs, budget and shared services 

operations, as well as the Office of the 

Commissioner’s executive operations. 

Realignments of the Office of 

Acquisitions and Grants Services, the 

Office of Executive Operations, the 

Office of Information Management, the 

Office of Management, the Office of 

Equal Employment Opportunity and 

Diversity Management, and the 

establishment of the Office of Financial 

Operations. 

Office of Foods: The Office of Foods 

will be realigned from the Office of 

Operations and will report directly to 

the Commissioner. 

Office of Policy, Planning and Budget: 

The Office of Policy, Planning and 

Preparedness will be retitled the Office 

of Policy, Planning and Budget. The 

realignments from the Office of Policy, 

Office of Planning, and the Office of 

Budget Formulation (formerly titled the 

Office of Budget Formulation and 

Presentation, Office of Operations). 

[Part D, Chapter D–B, (Food and Drug 

Administration), the Statement of 

Organization, Functions, and 

Delegations of Authority for the 

Department of Health and Human 

Services (35 FR 3685, February 25, 

1970, and 60 FR 56605, November 9, 

1995, 64 FR 36361, July 6, 1999, 72 FR 

50112, August 30, 2007) is amended to 

reflect the restructuring of the Office of 

the Commissioner (OC), Food and Drug 

Administration (FDA) as follows]. 

I. Under Part D, Food and Drug 

Administration, delete the Office of 

Commissioner in its entirety and replace 

with the following: 

DA.10 ORGANIZATION. The Food 

and Drug Administration (FDA) is 

headed by the Commissioner, Food and 

Drug, and includes the following 

organizational units: 

Office of the Commissioner 

Office of the Chief Counsel 

Office of the Chief of Staff 

Office of Legislation 

Office of Policy, Planning and Budget 

Office of Counselor to the 

Commissioner 

Office of Women’s Health 

Office of Special Medical Programs 

Office of External Affairs 

Office of Foods 

Office of the Chief Scientist 

Office of International Programs 

Office of Administration 

Office of Equal Employment 

Opportunity and Diversity Management 

Center for Tobacco Products 

DA.20 FUNCTIONS. 

Office of the Commissioner: The 

Office of the Commissioner (OC) 

includes the Commissioner and Deputy 

Commissioner who are responsible for 

the efficient and effective 

implementation of the FDA mission. 

Office of the Chief Counsel: The 

Office of the Chief Counsel (OCC) is also 

known as the Food and Drug Division, 

Office of the General Counsel, 

Department of Health and Human 

Services. While administratively within 

the Office of the Commissioner, the 

Chief Counsel is part of the Office of the 

General Counsel of the Department of 

Health and Human Services. 

1. Is subject to the professional 

supervision and control of the General 

Counsel, Department of Health and 

Human Services (DHHS), and represents 

FDA in court proceedings and 

administrative hearings with respect to 

programs administered by FDA. 

2. Provides legal advice and policy 

guidance for programs administered by 

FDA. 

3. Acts as liaison to the Department of 

Justice and other Federal agencies for 

programs administered by FDA. 

4. Drafts or reviews all proposed and 

final regulations and Federal Register 

notices prepared by FDA. 

5. Performs legal research and gives 

legal opinions on regulatory issues, 

actions, and petitions submitted to FDA. 


jlentini on DSKJ8SOYB1PROD with NOTICES